Download Cancer Treatment Project: Biotherapy: Interleukin

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
Texas State University San Marcos
School of Family and Consumer Sciences
MS in Human Nutrition and Foods
NUTR 5305-Seminar in Nutrition and Disease – Cancer Fall 2014
Dr. Ramona Salcedo-Price
Cancer Treatment Project
Biotherapy: Interleukin-2
Renal Cell Carcinoma
By: Lorena A. Saenz, Jenifer Tharani, Ana M. Hernández
Graduate Students MS in Human Nutrition and Foods
Date: November 5, 2014
Treatment: Biotherapy with IL-2
 Biotherapy is based on the principle of stimulating the
body's own immune response and/or using biological
substances against a disease, in this case cancer.1
 IL-2 is a glycoprotein produced by peripheral blood
lymphocytes and is a potent growth factor for activated
T-cells.2
 It has been shown to participate in tumor destruction
activity by inducing the growth of NK cells and LAK
cells which have the ability to kill tumor cells while
leaving normal cells unharmed.2
 IL-2 is one the most potent inducer of antitumor
activity in patients with advanced stage Renal Cell
Carcinoma.3,4
2
Figure A– Shows how Proleukin (man-made IL-2)
works to destroy tumor cells. 5
Diet Impact

Patients undergoing IL-2 treatment face malnutrition due to loss of appetite,
constant feeling of nausea, vomiting, diarrhea, fatigue and inability to
maintain a healthy body weight.1

Patients may develop mouth sores due to increased division of epithelial
cells in oral mucosa.5 Proper adjustments in food texture may be needed.

Low blood pressure may arise due to failure of sodium and potassium
homeostasis and anemia.

Studies have shown that IL-2 treatment may lead to changes in liver
function.

Patients may also experience lowered vitamin D metabolism, which has an
impact on calcium homeostasis.
3
4
7
5
6
5
References
1-Grant BL, Bloch AS, Hamilton KK, Thomson CA. Preparing for Cancer Treatment. In: Grant BL, Bloch AS, Hamilton KK,
Thomson CA. Complete Guide to Nutrition for Cancer Survivors. Atlanta, Georgia. American Cancer Society Health
Promotions;2010:154.
2-Mehta K, Ozpolat B, Gohil K, Aggarwal B.B. Recombinant proteins and genomics in cancer therapy. In: Principles of Cancer
Biotherapy. London, NY: Springer Science and Business Media; 2009: 61.
3-Lewko W, Oldham RK. Cytokines. In: Oldham RK, Dillman RO. Principles of Cancer Biotherapy. London, NY: Springer
Science and Business Media; 2009: 169-171.
4-Oldham RK. Biological therapy of genitourinary cancer. In: Principles of Cancer Biotherapy. London, NY: Springer Science and
Business Media; 2009: 645-647.
5-Prometheus Therapeutics & Diagnostics. Side Effects of Proleukin Interleukin-2. Available at:
http://www.proleukin.com/mrcc/side-effects-associated-with-proleukin-use.aspx Accessed November 3,2014
References for Patient Handout:
6- Grant BL, Bloch AS, Hamilton KK, Thomson CA. Coping with Changes in Eating and Digestion. In: Grant BL, Bloch AS,
Hamilton KK, Thomson CA. Complete Guide to Nutrition for Cancer Survivors. Atlanta, Georgia. American Cancer Society
Health Promotions;2010:227-262.
7- Academy of Nutrition and Dietetics. Management of Nutrition Impact Symptoms in Cancer and Education Handouts.
6